BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 14, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Mapatumumab: Phase II data

A Phase II trial to treat advanced MM showed that mapatumumab plus Velcade bortezomib missed the co-primary endpoints of significantly improving disease response and PFS vs. Velcade alone. As a result, Human Genome said it does not plan to continue development of the combination for the indication. Mapatumumab...

Read the full 226 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >